|
|
|
|
|
|
by architek1
4208 days ago
|
|
|
It appears GeNuero has found 47 million dollars from investment partner, Servier, and "GNbAC1 has successfully completed Phase IIa, demonstrating an optimal safety profile and encouraging signs of efficacy on a first small cohort of patients." http://www.geneuro.com/en/news.php#news |
|
|